Guidelines for the Treatment of Elderly Cancer Patients

Cancer Control

Volumn 10, Issue 6, 2003, Pages 445-453

  Lichtman, Stuart M ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTHRACYCLINE; BUSULFAN; CYCLOPHOSPHAMIDE; DIPHENOXYLATE; DOXORUBICIN; EPIPODOPHYLLOTOXIN; ETOPOSIDE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; IFOSFAMIDE; IRINOTECAN; LOPERAMIDE; METHOTREXATE; PACLITAXEL; PREDNISONE; TAMOXIFEN; TAXANE DERIVATIVE; TENIPOSIDE; VINBLASTINE; VINCRISTINE;

ANEMIA; BONE MARROW SUPPRESSION; CANCER REGRESSION; CANCER SURVIVAL; CANCER THERAPY; COMORBIDITY; DIARRHEA; ELDERLY CARE; HUMAN; MUCOSA INFLAMMATION; PALLIATIVE THERAPY; POLYPHARMACY; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; TREATMENT PLANNING; VALIDATION PROCESS;

EID: 0345168137     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480301000602     Document Type: Review

References (94)

1. Balducci L, Yates J. General guidelines for the management of older patients with cancer. Oncology (Huntingt). 2000;14:221-227.
2. Winn RJ, McClure J. The NCCN clinical practice guidelines in oncology: a primer for users. J Natl Compr Cancer Network. 2003;1:5-13. Available at: http://www.nccn.org. Accessed September 18, 2003.
3. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer. 1997;80:1273-1283.
4. United States life tables, 2000. Natl Vital Stat Rep. 2002;51:1-38.
5. Yancik R, Yates JW, eds. Cancer in the Elderly: Approaches to Early Detection and Treatment. New York, NY: Springer Publishing Co; 1989.
6. Yee KW, Pater JL, Pho L, et al. Enrollment of older patients in cancer treatment trials in canada: why is age a barrier? J Clin Oncol. 2003;21:1618-1623.
7. Begg CB, Carbone PP. Clinical trials and drug toxicity in the elderly: the experience of the Eastern Cooperative Oncology Group. Cancer. 1983;52:1986-1992.
8. Begg CB, Elson PJ, Carbone PP. A study of excess hematologic toxicity in elderly patients treated on cancer chemotherapy protocols. In: Yancik R, Yates JW, eds. Cancer in the Elderly: Approaches to Early Detection and Treatment. New York, NY: Springer Publishing Co; 1989.
9. Monfardini S, Sorio R, Boes GH, et al. Entry and evaluation of elderly patients in European Organization for Research and Treatment of Cancer (EORTC) new-drug-development studies. Cancer. 1995; 76:333-338.
10. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
11. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994;120:104-110.
12. Yancik R, Wesley MN, Ries LA, et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer. 1998;82:2123-2134.
13. Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16:1582-1587.
14. Repetto L, Granetto C, Venturino A, et al. Prognostic evaluation of the older cancer patient. In: Balducci L, Lyman GH, Ershler WB, eds. Comprehensive Geriatric Oncology. Amsterdam, the Netherlands: Harwood Academic Publishers; 1998.
15. Rockwood K, Stadnyk K, MacKnight C, et al. A brief clinical instrument to classify frailty in elderly people. Lancet. 1999;353:205-206.
16. Reuben DB, Rubenstein LV, Hirsch SH, et al. Value of functional status as a predictor of mortality: results of a prospective study. Am J Med. 1992;93:663-669.
17. Repetto L, Vercelli M, Simoni C, et al. Comorbidity among elderly patients with and without cancer. Proc Annu Meet Am Soc Clin Oncol. 1994;13:1625. Abstract.
18. Hamerman D. Toward an understanding of frailty. Ann Intern Med. 1999;130:945-950.
19. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146-156.
20. Morris LA, Grossman R, Barkdoll G, et al. Information search activities among elderly prescription drug users. J Health Care Mark. 1987;7:5-15.
21. Schmucker DL. Drug disposition in the elderly: a review of the critical factors. J Am Geriatr Soc. 1984;32:144-149.
22. Yuen GJ. Altered pharmacokinetics in the elderly. Clin Geriatr Med. 1990;6:257-267.
23. Baker SD, Grochow LB. Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med. 1997;13:169-183.
24. Egorin MJ. Cancer pharmacology in the elderly. Semin Oncol. 1993;20:43-49.
25. Rossman I, ed. Clinical Geriatrics. 2nd ed. Philadelphia, Pa: Lippincott; 1979.
26. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol. 1997;8:963-968.
27. Teicher BA, Ara G, Herbst R, et al. PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy. In Vivo. 1997;11:301-311.
28. Schrijvers D, Highley M, De Bruyn E, et al. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Anticancer Drugs. 1999;10:147-153.
29. Rieseman C. Antidepressant drug interactions and the cytochrome p450 system: a critical appraisal. Pharmacotherapy. 1995;15(6 pt 2):84S-99S.
30. Michalets EL. Update: clinically significant cytochrome p-450 drug interactions. Pharmacotherapy. 1998;18:84-112.
31. Evans W, Schentag J, Jusko W, eds. Applied Pharmacokinetic: Principles of Therapeutic Drug Monitoring. 3rd ed. Vancouver, Wa: Applied Therapeutics Inc; 1992.
32. Flockhart D. Cytochrome p450 drug interaction table. Available at http://medicine.iupui.edu/flockhart/. Accessed September 12, 2003.
33. Sotaniemi EA, Arranto AJ, Pelkonen O, et al. Age and cytochrome p450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther. 1997;61:331-339.
34. Vestal RE. Aging and pharmacology. Cancer. 1997;80:1302-1310.
35. Balducci L, Corcoran MB. Antineoplastic chemotherapy of the older cancer patient. Hematol Oncol Clin North Am. 2000;14:193-212.
36. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med. 1982;307:652-659.
37. Tauchi H, Tsuboi K, Okutoni J. Age changes in the human kidney of the different races. Gerontologia. 1971;17:87-97.
38. Evers BM, Townsend CM Jr, Thompson JC. Organ physiology of aging. Surg Clin North Am. 1994;74:23-39.
39. Gelman RS, Taylor SG IV. Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol. 1984;2:1404-1413.
40. Swedko PJ, Clark HD, Paramsothy K, et al. Serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch Intern Med. 2003;163:356-360.
41. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
42. Jelliffe RW. Estimation of creatinine clearance when urine cannot be collected. Lancet. 1971;1:975-976.
43. Burkhardt H, Bojarsky G, Gretz N, et al. Creatinine clearance, Cockcroft-Gault formula and cystatin C: estimators of true glomerular filtration rate in the elderly? Gerontology. 2002;48:140-146.
44. Smythe M, Hoffman J, Kizy K, et al. Estimating creatinine clearance in elderly patients with low serum creatinine concentrations. Am J Hosp Pharm. 1994;51:198-204.
45. Wright JG, Boddy AV, Highley M, et al. Estimation of glomerular filtration rate in cancer patients. Br J Cancer. 2001;84:452-459.
46. Marx GM, Steer CB, Galani E, et al. Evaluation of the Cockroft Gault, Jelliffe and Wright formulae in estimating renal function in elderly patients. Proc Annu Meet Am Soc Clin Oncol. 2002;21:1486. Abstract.
47. Balducci L, Extermann M. Cancer chemotherapy in the older patient: what the medical oncologist needs to know. Cancer. 1997;80:1317-1322.
48. Skirvin JA, Lichtman SM. Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer. Drugs Aging. 2002;19:25-42.
49. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748-1756.
50. Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst. 1995;87:573-580.
51. Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev. 1995;21:33-64.
52. Kastrissios H, Blaschke TF. Medication compliance as a feature in drug development. Annu Rev Pharmacol Toxicol. 1997;37:451-475.
53. Bonadonna G, Valagussa P Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981;304:10-15.
54. Lebovits AH, Strain JJ, Schleifer SJ, et al. Patient noncompliance with self-administered chemotherapy. Cancer. 1990;65:17-22.
55. Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med. 1990;150:841-845.
56. Cramer JA. Enhancing patient compliance in the elderly: role of packaging aids and monitoring. Drugs Aging. 1998;12:7-15.
57. Richardson JL, Shelton DR, Krailo M, et al. The effect of compliance with treatment on survival among patients with hematologic malignancies. J Clin Oncol. 1990;8:356-364.
58. Levine AM, Richardson JL, Marks G, et al. Compliance with oral drug therapy in patients with hematologic malignancy. J Clin Oncol. 1987;5:1469-1476.
59. Richardson JL, Marks G, Levine A. The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol. 1988;6:1746-1752.
60. Lee CR, Nicholson PW, Souhami RL, et al. Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer. Br J Cancer. 1993;67:630-634.
61. Urquhart J. Patient compliance with crucial drug regimens: implications for prostate cancer. Eur Urol. 1996;29:124-131.
62. Partridge AH, Avorn J, Wang PS, et al. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94:652-661.
63. Ania BJ, Suman VJ, Fairbanks VF, et al. Incidence of anemia in older people: an epidemiologic study in a well defined population. J Am Geriatr Soc. 1997;45:825-831.
64. Chaves PH, Ashar B, Guralnik JM, et al. Looking at the relationship between hemoglobin concentration and prevalent mobility difficulty in older women: should the criteria currently used to define anemia in older people be reevaluated? J Am Geriatr Soc. 2002;50:1257-1264.
65. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865-2874.
66. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol. 2002;20:4083-4107.
67. Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst. 2001;93:1204-1214.
68. Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000;5:224-237.
69. Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002;95:888-895.
70. Christman K, Muss HB, Case LD, et al. Chemotherapy of metastatic breast cancer in the elderly: the Piedmond Oncology Association experience. JAMA. 1992;268:57-62.
71. Ibrahim NK, Frye DK, Buzdar AU, et al. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer: tolerance and outcome. Arch Intern Med. 1996;156:882-888.
72. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002-1006.
73. Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med. 2002;112:406-411.
74. Balducci L, Lyman GH. Patients aged ≥ 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy. J Clin Oncol. 2001;19:1583-1585.
75. Osby E, Hagberg H, Kvaloy S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood. 2003;101:3840-3848.
76. Zinzani PL, Pavone E, Storti S, et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood. 1997;89:3974-3979.
77. Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol. 2000;18:3558-3585.
78. Stein BN, Petrelli NJ, Douglass HO, et al. Age and sex are independent predictors of 5-fluorouracil toxicity: analysis of a large scale phase III trial. Cancer. 1995;75:11-17.
79. Popescu RA, Norman A, Ross PJ, et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol. 1999;17:2412-2418.
80. Chiara S, Nobile MT, Vincenti M, et al. Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol. 1998;42:336-340.
81. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345:1091-1097.
82. Lichtman SM, Skirvin JA, Vemulapalli S. Pharmacology of antineoplastic agents in older cancer patients. Crit Rev Oncol Hematol. 2003;46:101-114.
83. Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev. 1995;21:33-64.
84. Cancer Therapy Evaluation Program. Common Toxicity Criteria V2. Available at: http://ctep.cancer.gov/reporting/Ctc-3.html. Accessed September 24, 2003.
85. Skirvin J, Relias V. Topoisomerase inhibitors: 2. Irinotecan. J Oncol Pharm Practice. 1998;4:103-116.
86. Rothenberg ML, Cox JV, DeVore RF, et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer. 1999;85:786-795.
87. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998;352:1407-1412.
88. Kehrer DF, Sparreboom A, Verweij J, et al. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res. 2001;7:1136-1141.
89. Govindarajan R, Heaton KM, Broadwater R, et al. Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet. 2000;356:566-567.
90. Trifan OC, Durham WF, Salazar VS, et al. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res. 2002;62:5778-5784.
91. Zidan J, Haim N, Beny A, et al. Octreotide in the treatment of severe chemotherapy-induced diarrhea. Ann Oncol. 2001;12:227-229.
92. Repetto L, Balducci L. A case for geriatric oncology. Lancet Oncol. 2002;3:289-297.
93. Lachs MS, Feinstein AR, Cooney LM Jr, et al. A simple procedure for general screening for functional disability in elderly patients. Ann Intern Med. 1990;112:699-706.
94. Saliba D, Elliott M, Rubenstein LZ, et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 2001;49:1691-1699.